Clinical Ophthalmology (May 2024)
Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting
Abstract
Arsalan Akbar Ali,1 Denisse Avilés Elescano,2 Davinder S Grover3 1Anne Burnett Marion School of Medicine, Texas Christian University, Fort Worth, TX, USA; 2Universidad San Martin de Porres (USMP), Lima, Peru; 3Glaucoma Associates of Texas, Dallas, TX, USACorrespondence: Davinder S Grover, Glaucoma Associates of Texas, 10740 N Central Expressway, Suite 300, Dallas, TX, 75231, USA, Email [email protected]: To characterize clinical outcomes following a single administration of bimatoprost SR in eyes with glaucoma in a real-world setting implanted at the slit-lamp.Setting: Tertiary care Glaucoma practice, Glaucoma Associates of Texas, Dallas, Texas.Design: Retrospective interventional case series.Methods: Data were analyzed from consecutive patients receiving a single bimatoprost SR implant from the time of its approval to the time of data collection. All eyes were implanted at the slit-lamp. Eyes with less than 1 month of follow-up were excluded. The primary outcome was median time to next intraocular pressure (IOP)-lowering intervention. Mean IOP and medication use, and changes from baseline, were also assessed through 12 months of follow-up.Results: Overall 129 eyes of 81 patients were analyzed. Following bimatoprost SR administration (replacing a topical prostaglandin analogue [PGA] in most eyes), the median survival time without any further IOP-lowering interventions was between 6– 9 months. Mean IOP remained unchanged from baseline at month 1 (consistent with switch from topical to intracameral PGA therapy) and began to rise at month 3. At month 12, 40.5% of eyes (52 eyes) remained intervention-free, mean medication reduction was 0.5 medications per eye, and 27.8% of eyes (36 eyes) were medication-free. Adverse events were uncommon and most were transient and resolved with or without intervention.Conclusion: This real-world analysis of bimatoprost SR use for glaucoma therapy complements Phase 3 study findings and demonstrates that the implant can safely provide medication reduction through 6 months in most eyes and through 12 months in almost 40% of eyes.Keywords: glaucoma, bimatoprost SR, durysta, sustained release
